Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases
Authors' conclusion
Japanese people with T2D and G3 CKD initiating an SGLT2i had a lower risk of renal events than people initiating an oGLD.
Study context
- Population
- Japanese people with T2D and G3 chronic kidney disease (CKD) (eGFR ≥ 30 to < 60 mL/min/1.73 m²) newly prescribed an SGLT2i or an oGLD, April 2014 to November 2021; Medical Data Vision and Real-World Data databasesmatched cohorts in 2 databases
- Exposure
- SGLT2i vs other glucose-lowering drugs
- SGLT2in = 1,595 (MDV-DB); 1,286 (RWD-DB)
- oGLDn = 1,595 (MDV-DB); 1,286 (RWD-DB)reference
- Outcome
- Composite of:
- Development of end-stage kidney disease
- Sustained eGFR decline ≥50%
Methodological detailspropensity-score matched (1:1), two medical administrative databases (Medical Data Vision database (MDV-DB), Real-World Data database (RWD-DB))
- Propensity-score matched (1:1)
- Two medical administrative databases (MDV-DB, RWD-DB)
Main finding
As reported in the abstract
Composite renal outcome
SGLT2i vs oGLDHazard ratio (95% CI)P value
MDV-DB (1595 per group)
0.49(0.33–0.74)
P < 0.001RWD-DB (1286 per group)
0.57(0.37–0.88)
P = 0.011Observational data: associations, not effects.
Original publication
Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases. Diabetes Obes Metab. Published 27 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →